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Abstract
Background: In mammals succinic semialdehyde dehydrogenase (SSADH) plays an essential role in the metabolism of the
inhibitory neurotransmitter c-aminobutyric acid (GABA) to succinic acid (SA). Deficiency of SSADH in humans results in
elevated levels of GABA and c-Hydroxybutyric acid (GHB), which leads to psychomotor retardation, muscular hypotonia,
non-progressive ataxia and seizures. In Escherichia coli, two genetically distinct forms of SSADHs had been described that are
essential for preventing accumulation of toxic levels of succinic semialdehyde (SSA) in cells.
Methodology/Principal Findings: Here we structurally characterise SSADH encoded by the E coli gabD gene by X-ray
crystallographic studies and compare these data with the structure of human SSADH. In the E. coli SSADH structure, electron
density for the complete NADP
+ cofactor in the binding sites is clearly evident; these data in particular revealing how the
nicotinamide ring of the cofactor is positioned in each active site.
Conclusions/Significance: Our structural data suggest that a deletion of three amino acids in E. coli SSADH permits this
enzyme to use NADP
+, whereas in contrast the human enzyme utilises NAD
+. Furthermore, the structure of E. coli SSADH
gives additional insight into human mutations that result in disease.
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Introduction
Succinic semialdehyde dehydrogenase (SSADH) belongs to the
aldehyde dehydrogenases (ALDH) superfamily [1] and has been
identified and purified from mammals [2,3,4,5] as well as from
microorganisms [6,7,8]. SSADH plays a key role in mammalian
neurobiology, where it functions in the metabolic pathway termed
the‘‘c-aminobutyricacid (GABA)shunt’’ inthe brain.IntheGABA
shunt, the inhibitory neurotransmitter GABA is synthesised from
glutamic acid by glutamic acid decarboxylase (GAD) [9,10]. GABA
is then metabolised in a two-step reaction. First, GABA-transam-
inase (EC 2.6.1.19) catalyses the breakdown of GABA in the
presence of a-ketoglutarate to produce succinic semialdehyde (SSA)
and glutamic acid (Figure 1). SSA is then converted to succinic acid
(SA) by the NAD
+/NADP
+-dependant enzyme succinic semialde-
hyde dehydrogenase (SSADH; EC 1.2.1.24) [11]. Hence, GABA is
channelled into the tricarboxylic acid cycle in the form of SA.
Alternatively, SSA can be converted to c-hydroxybutyric acid
(GHB) by succinic semialdehyde reductase [12] (see Figure 1).
Autosomal deficiency of SSADH results [13,14] in serious
disease, with patients displaying varying degrees of psychomotor
retardation, muscular hypotonia, non-progressive ataxia and
seizures [15,16]. As a result of a failure to properly metabolise
SSA, SSADH deficiency leads to an accumulation of GABA, SSA
and GHB (Figure 1). Accordingly, patients exhibit a ,230 fold
[17,18] increase in levels of cerebrospinal fluid GHB as well as a
modest 3-fold increase in GABA levels [16,17,19,20]. The increase
in GABA, SSA as well as GHB levels are all thought to contribute
to SSADH deficiency disease through a complex range of
signalling and developmental effects (for a comprehensive review
see Knerr et.al.[18]).
In Escherichia coli [21], like in mammals, SSA can cause oxidative
damage and two SSADH genes, the gabD and sad (also called yneI)
genes, have been identified [21]. The gabD gene encodes a NADP
+
dependent SSADH (EC 1.2.1.24) and is located in the gab operon.
The products of the gab operon (which comprises gabT (c-
aminobutyrate transferase), gabD (SSADH), gabP (GABA perme-
ase) and gabC (a regulatory gene) [22]) drive GABA catabolism and
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The sad gene encodes for a NAD
+ dependent SSADH (EC
1.2.1.16 and shares 32% identity with gabD) and is an orphan
gene[25]. The sad gene is induced by exposure to exogenous SSA
and functions primarily to prevent its accumulation in the cell.
Furthermore, the sad gene product may also enable growth on
putrescine as the nitrogen source [25].
Recently, the structure of human SSADH has been published
[26]. These data suggest that a redox switch mediated via a
reversible disulfide bond (between Cys340 and Cys342) in the
catalytic loop regulate human SSADH activity such that formation
of the disulfide bond results in the catalytic loop adopting a closed
conformation that blocks access to the substrate and cofactor
binding sites. Reduction of the disulfide bond leads to a large
structural change where the catalytic loop switches to an open
conformation permitting access to the substrate and cofactor
binding sites (r.m.s.d. 4.1 A ˚ over 11 residues of the catalytic loop).
Shortly after the human SSADH structure was published, the
structure of SSADH from Burkholderia pseudomallei, without a
substrate or cofactor (PDB ID: 3ifg and 3ifh), was deposited into
the PDB by the Seattle Structural Genomic Centre for Infectious
Disease.
Despite these recent studies, the structural information of
SSADH and its interactions with cofactor remains scarce. Here we
report a 2.3 A ˚ X-ray crystal structure of the gabD gene product
(NADP
+-dependant) SSADH from E. coli [1] which shares 54%
identity with the human SSADH. Comparison of the two SSADH
structures suggests that E. coli SSADH is also redox regulated,
furthermore it reveals that the bacterial SSADH is structurally
suited for NADP
+, rather than NAD
+ (as utilised by its human
counterpart).
Results and Discussion
Production and Characterisation of E. coli SSADH
Recombinant E. coli SSADH was purified as a tetrameric
molecule (determined by analytical size-exclusion chromatogra-
phy; data not shown) which is in agreement with the previous
description in the literature [6]. The conversion of SSA to SA by
purified SSADH was confirmed by
1H NMR, as shown in Figure
S1. At pH 8.0 and under the condition as described in the
materials and methods, the Km of the purified enzyme is
16.9462.2 mM and Vmax is 40.9261.3 mM. The enzyme activity
measured in the presence of NADP
+ is approximately 20-fold
higher than that measured in the presence of NAD
+ (data not
shown) as described previously [27].
The X-Ray Crystal Structure of SSADH
The structure of E. coli SSADH reveals four monomers (A–D, 481
amino acid per monomer) in the asymmetric unit (Figure 2),
forming,likeothermembersofthealdehydedehydrogenase(ALDH)
family, a biologically relevant homotetramer [28,29,30,31,32] with
the 4 monomers related by a non-crystallographic 222 symmetry.
The four monomers can be superposed with root-mean-square
deviation (r.m.s.d: over all Ca’s) of 0.193 to 0.377 A ˚.M o n o m e r sA B
and CD form obligate dimers, which then assemble into a functional
tetramer [32]. For the initial description of the structure, we refer
primarily to monomer A.
The SSADH monomer (Figure 2A) adopts a typical NAD(P)
+
dehydrogenase fold with four b sheets (A–D) and 13 a helices
(1–13). The secondary structure assignments used in this report are
as shown in Figure S2. The L-shaped molecule consists of three
domains: The catalytic domain (residues 256–439), the cofactor
binding domain (1–124, 146–254 and 446–471) and the
oligomerisation domain (residues 125–147, 472–481). In each
monomer, the cofactor NADP
+ is bound to the active site giving
rise to a binary complex, whereas the structure of the N-terminal
His-tag was not resolved.
The catalytic domain consists of a central 7 stranded b-sheet
(the D-sheet) flanked by 2 helices on one side and 3 helices on the
other. The catalytic loop (residues 282–290) is located adjacent to
the cofactor binding site. The cofactor binding domain interacts
with NADP
+ via two tandem Rossmann folds in a (ba)4b
formation. This is a variation of the classic Rossmann fold [33],
where the last b strand of first (ba)2b motif (residues 148–208)
forms the first b strand of the second (ba)2b motif (residues
205–254). The oligomerisation domain comprises an elongated
3-stranded b-sheet (the B-sheet), which interacts with two other
monomers in the final tetrameric assembly.
The obligate dimer (A+B, C+D) is formed by domain swap-
ping; such that strand s3B of the oligomerisation domain in
monomer A forms b-sheet hydrogen bonding with strand s7D of
the catalytic domain in monomer B to make a 10 stranded b-sheet
(Figure 2B). The screw axis of the non-crystallographic 2-fold
symmetry is centred on the C b-sheet of the Rossmann fold.
A total of 34 H-bonds and 13 salt bridges are made between
the monomers with ,2470 A ˚ 2 buried in the dimer interface
(Table S1).
Figure 1. Enzymes and metabolites involved in the GABA shunt. Enzymes catalysing reactions are numbered, (1) glutamate decarboxylase
(GAD), (2) c-aminobutyric transaminase (GABA-T), (3) succinic semialdehyde dehydrogenase (SSADH) and (4) succinic semialdehyde reductase (SSR).
The blue highlighted boxes show enzymes that are found in the gab operon of E. coli. The thick black line indicates the pathway is blocked, SSA is
then converted to c-hydroxybutyrate (GHB) by succinic semialdehyde reductase (SSR), pathway coloured in red, which is described in SSDAH
deficiency. Figure adapted from Blasi et al. [9]
doi:10.1371/journal.pone.0009280.g001
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PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9280Figure 2. Crystal structure of E. coli SSADH. a) Two cartoon representations of E. coli SSADH monomer (rotated by 180u) with NADP
+ bound
(orange) comprises of the catalytic domain (blue and light blue) with catalytic loop (red), the cofactor binding domain (green and yellow, where
yellow illustrates the Rossmann fold) and the oligomerisation domain (magenta); b) A cartoon representation of the E. coli SSADH dimer with NADP
+
bound (orange), it can be seen that the 3-stranded oligomerisation domain b- sheet (dark green) of the green monomer is extending the 7-stranded
catalytic domain b- sheet (dark blue) of the blue monomer to form a 10-stranded b- sheet. c) Two surface representation models of the SSADH
tetramer (rotated by 180u) showing the dimer of dimer formation between the blue and red monomer and the green and light blue monomers.
NADP
+ (orange) can be seen on the same face of the dimer, the substrate binding pocket has also been labelled.
doi:10.1371/journal.pone.0009280.g002
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AB and CD via a 90u rotation (Figure 2C) with ,1630 A ˚ 2 buried
in the interface and 10 H-bonds (Table S1). Strand s1B of the
oligomerisation domain of monomer A and that of monomer C sit
side-by-side and the two b-sheets form a V-shape at the interface.
Monomer B forms similar interactions with monomer D. Contacts
form between all monomers with respect to Monomer A are listed
in Table S1.
Structural Comparison of Human and E. coli SSADH
The structure of human SSADH in both the active (open,
reduced; PDB ID: 2w8o) and inactive (closed, oxidised; PDB ID:
2w8n) state has recently been determined [26]. E. coli SSADH was
purified and crystallised in the presence of the reducing agent
b-mercaptoethanol, and accordingly, the structure we report most
closely resembles the active form of human SSADH (2w8o) and
superposes with a root-mean-square deviation of 0.79 A ˚ over 472
Ca (2w8o and Monomer A, Figure 3A and Figure S2). The
structure of the catalytic loop in E. coli and human SSADH is
essentially identical, furthermore, the two cysteine residues
involved in the redox switch in human SSADH are conserved in
E. coli (Figure S2). These data suggest that E. coli SSADH may also
be regulated via the redox status of the surrounding milieu.
Significantly, our results show that E. coli gabD gene product is
inactive in the presence of H2O2 and can be reactivated upon
addition of DTT (Figure S3). Interestingly, the other E. coli
SSADH gene, sad, does not contain the dual conserved cysteine
residues in the catalytic loop and therefore it may not be regulated
via the same redox mechanism.
Comparison of human and E. coli SSADH reveals two major
regions of structural variation: the first involves the cofactor
binding site (discussed below; Figure 3B). The second is the loop
K380-F387 of E. coli (L433–F440 in human SSADH; r.m.s.d.
3.4 A ˚ over 10 residues: Figure 3C) in the catalytic domain. The
structure observed in E. coli SSADH (K380–F387) resembles the
canonical ALDH fold [28,29,30,31,32] and permits the conserved
glutamate (E385) to bind to the nicotinamide ribose moiety of
NADP+. Neither the nicotinamide nor the ribose moieties were
visible in electron density in the human SSADH structures: and it
is likely that this mobility may impact on the L433–F440 loop.
The Substrate and Cofactor Binding Sites in E. coli SSADH
In each SSADH monomer, the catalytic residues are located at
the centre of the molecule with two funnel-like openings on the
surface of either side of the molecule. The larger opening functions
to allow entry of the cofactor NADP
+ (Figure 4A, B). On the
opposite side of the monomer, the smaller opening is located, and
this cavity is utilized for substrate entry and product exit
(Figure 4C, D, 2C) as for other ALDHs.
E. coli SSADH was crystallised in the presence of both NADP
+
and SSA. We observe no electron density for the substrate.
However, superposition between human and E. coli SSADH does
permit us to identify the substrate binding pocket (Figure 5).
The conserved catalytic residues (C340 and E306) and the
active site residues (R213, R334 an S498) of human SSADH
structures (PDB ID: 2w8o and 2w8q)[26] superpose well with that
of E. coli SSADH (C288 and E254; R164, R282 and S445
respectively, Figure 5, Figure S2) [26].
Catalytic Mechanism of SSADH
The catalytic mechanism for ALDH enzymes is well char-
acterised. The first step of the reaction is nucleophilic attack by the
catalytic C288 residue on SSA to give the hemithioacetal
intermediate. Hydride transfer from this intermediate to NAD(P)
+
results in formation of the thioacyl enzyme intermediate and
NAD(P)H. Lastly, the conserved E254 residue acts as a general
base to deprotonate a water molecule prior to its attack on the
thioacyl enzyme intermediate resulting in formation of SA and
regeneration of the C288 residue. The general base, E254, in all
monomers can be modelled in two alternative conformations
according to the electron density. It is suggested that the two
conformations of E254 is likely to be associated with different
stages of the catalytic process, with one conformation ‘‘a’’ (Figure 5)
being for hydride transfer and conformation ‘‘b’’ for hydrolysis.
In the E. coli SSADH structure, electron density for the cofac-
tor in the binding sites is clearly evident (Figure 6). Surface
representation of the cofactor binding site illustrates where the
cofactor is positioned; also shown is the human structure (PDB ID:
2w8r)[26] in which the cofactor NAD
+ is soaked into the binding
site of the C340A mutant (Figure 4A, B). The cofactor binding site
comprises two pockets; one of which is close to the surface of the
SSADH molecule and accommodates the adenosine (adenine and
the first ribose) and the 2’phosphate. The second pocket is located
centrally in the active site and accommodates the second ribose
and the nicotinamide.
A key difference between these two enzymes is that human
SSADH utilizes NAD
+ as a cofactor, whereas E. coli SSADH utilizes
NADP
+. Our structural data reveals the basis for this preference - in
E. coli SSADH a three-residue deletion (of the human sequence
261RKN263, Figure S2) in the loop connecting s5C and h6 permits
accommodation of the extra phosphate group of NADP
+
(2’phosphate: Figure 3B, 4A and B). Interestingly, although E. coli
SSADH can utilise NAD
+ as a cofactor the activity in the presence
of this molecule is only 1/20 of that of NADP
+ (data not shown). In
human SSADH, 261RKN263 (Figure 3B and 4A) occupies the space
for the 2’phosphate of NADP
+; consequently, only NAD
+ but not
NADP
+ can be utilised as a cofactor for this enzyme.
Importantly our structural data permits unambiguous place-
ment of the entire NADP
+ moiety including that of the
nicotinamide ring in each active site (Figure 6, Table S2). This
is in contrast to other published ALDH structures (including the
human SSADH structures) where the nicotinamide ring is often
partially disordered, indicating flexibility. In our structure, the
NO2 and NO3 of the nicotinamide ribose interacts with E385 and
K338 respectively; while NO7 of the nicotinamide ring binds to
the backbone of L255 and G232 of the catalytic domain (Figure 6,
Table S2). Such interactions are rarely observed, in particular, this
region is disordered (suggesting flexibility) in the human SSADH
structure (PDB ID: 2w8r)[26].
Amongst the well defined cofactor crystal structures, three
different conformations of NAD(P)
+ found in the ALDH
superfamily have been described [29]–the hydride transfer (PDB
ID: 1bpw [31]), the hydrolysis (see below) and the ‘‘out’’
conformation (PDB ID: 2ilu [29]; Figure 7). Superposition with
ALDH structures in the hydrolysis conformation (PDB ID: 1bxs
and 1O01 [34,35]) reveals that the cofactor in the E. coli SSADH
structure most closely resembles this conformation, where the
nicotinamide ring is retracted from the active site such that the
general base E251 is now situated in an ideal distance (3.69 A ˚ to
the substrate SSA and 3.15 A ˚ to the catalytic cysteine C288) to
catalyse the deacylation process.
Analysis of E. coli SSADH Structure with Respect to
Human Disease-Linked Mutations
To date, more than 40 mutations found in patients with SSADH
deficiency (Table 1 & 2) have been documented in the literature
[9,36,37,38,39,40,41] (in this work, all numbering of point
mutations use human SSADH numbering with E. coli SSADH
SSADH X-Ray Crystal Structure
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truncations, deletions, insertions as well as splice site mutants
(Table 1). However, eighteen point mutations (all missense) are
found in the coding sequence, one of which (G36R) is located at the
mitochondrial targeting sequence (Table 2). The remaining 17
variants are mapped onto the E. coli SSADH structure (Figure 8,
Table 2). Of these, six mutations (G36R, H180Y, P182L, A237S,
N372S and V406I) are most likely non-pathogenic [42]. Of the
mutations associated with disease, five mutations map to four
positions in the catalytic domain (N335K, P382L/Q, G409D,
V487E); four are found in the cofactor binding domain (C223Y,
T233M, N255S and G268E); and two are mapped to the
oligomerisation domain (G176R and G533R). Mutations that lead
toadramaticdecreaseofenzymeactivity(2%orlessofthewildtype)
are found to be strictly conserved between human/E.coli SSADH
(G176R/G127, G268E/G216, N335K/N283, P382L/P329,
G409D/G356, G533R/G480). All these residues superpose well
between the human and E. coli structures (Figure S4).
Figure 3. A single molecule superposition of E. coli SSADH and human SSADH. A) Ca trace of monomer A of E. coli SSADH (green)
superposed with the human SSADH molecule (PDB ID: 2w8r [26]: yellow: r.m.s.d.=0.712 over 473 residues), with the NADP
+ moiety (orange) from E.
coli SSADH. Two structurally variable regions have been highlighted with dashed lines and labelled B–C. Figures B–C show Ca traces of all four E. coli
SSADH monomers A–D (green) and 5 human SSADH monomers (open loop, PDB ID: 2w8o, 2w8p, 2w8q, 2w8r yellow; closed loop, PDB ID: 2w8n
magenta)[26] superposed onto each other, only one NADP
+ molecule (orange) from monomer A of E. coli SSADH is shown. B) Shows the region
surrounding the 3 amino acid insertion (261RKN263) in human SSADH, which clashes with the 2’phosphate of NADP
+. C) The loop motif connecting
s2D and s3D in the catalytic domain, residues A379–G388 in E. coli SSADH and M432–G441 in human SSADH (r.m.s.d. of 3.4 A ˚ over 10 residues). The E. coli
SSADH loop is conserved throughout the ALDH family and is stabilised by 7 hydrogen bonds. The novel loop in human SSADH is stabilised by only 3
hydrogen bonds, furthermore this same loop in the reduced wild type human SSADH (PDB ID: 2w8o)[26] is highly flexible and could not be
determined using X-ray crystallography.
doi:10.1371/journal.pone.0009280.g003
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SSADH plays an essential role in living organisms including the
central nervous system, both in development and in cognitive
function [43]. However, relatively little is known about the
chemistry of the active site of SSADH. In the present study, we
begin to address this problem by determining the 2.3 A ˚ X-ray
crystal structure of SSADH from E. coli.
One key difference between human and E. coli SSADH is that
the human enzyme utilises NAD
+ as a cofactor, whereas the
bacterial counterpart uses NADP
+. Interestingly, analysis of
sequence alignments reveals a single sequence insertion event of
three amino acids (R206, K207, N208, Figure S2) in human
SSADH. This insertion maps to the loop between Strand s5C and
a6 in the Rossmann fold which in E. Coli SSADH forms the pocket
that binds the 2’phosphate group of NADP
+. Given that NAD
+
does not contain the 2’phosphate group, we postulate that the
insertion of the two positively charged residues may restrict the
adenosine-binding pocket of human SSADH to bind NAD
+ rather
than NADP
+. Related to this observation, we also note that a
splice variant of human SSADH has been characterised that
involves a 12 amino acid substitution and a shortening of the h5
helix. While the expression levels of this variant has not been
characterised we speculate that it is possible that this substitution
would open up the adenosine- binding pocket and may permit
binding of the alternative cofactor NADP
+.
Our structural data also permit us to analyse human SSADH
mutations that cause disease, our analysis reveals that human point
mutations associated with SSADH deficiency mutations cluster in
Figure 4. Comparisons between human (PDB ID: 2w8r)[26] and E.coli (monomer A) SSADH cofactor binding and SSA binding
pockets, visualised using electrostatic surface representations (red represents negatively charged surfaces and blue represents
positively charged surfaces). A–B) both human (A: NAD
+ in yellow) and E. coli (B: NADP
+ in orange) SSADH have a two pocket NAD(P)
+ binding
site per molecule, the first (mostly blue), positively charged and close to the surface, accommodates the adenosine moiety (and the 2’phosphate in E.
coli SSADH). The second binding pocket, deep in the active site, houses the nicotinamide ribose moiety (absent in human SSADH). The smaller human
SSADH cofactor binding pocket has a large positive protrusion, which closes the bottom of the pocket, while the larger E. coli SSADH cofactor binding
pocket can clearly accommodate the 2’phosphate of the NADP
+. C–D) shows the positively charged SSA binding pocket of both human (C) and E. coli
(D) SSADH highlighted by a white dashed line. The human SSA binding pocket is larger than the E. coli SSA binding pocket.
doi:10.1371/journal.pone.0009280.g004
SSADH X-Ray Crystal Structure
PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9280three key areas. One group of mutations affect the cofactor
binding domain, a second group directly impact on the catalytic
domain and, finally, several mutations involve residues that appear
to be important for formation of the dimer and/or the tetramer.
The latter mutations are of particular interest, since they
demonstrate how important homo-tetramerisation is for biological
activity. It is important to note, however, that each monomer
contains a complete catalytic unit, i.e. that no part of the catalytic
machinery is contributed in trans from another monomer. The
precise contribution of SSADH tetramer formation to its
biological function remains to be understood. However, it is
worth noting that many members of the ALDH family are
allosterically regulated (see for example [44]).
To conclude, our work provides additional structural insight
into an important enzyme that in humans regulates metabolism of
the neurotransmitter glutamate and GABA. Perturbation of
GABA levels have been linked to many different neurological
diseases, including depression and movement disorders [45].
Therefore there is much clinical interest in enzymes that impact on
levels of GABA and related molecules. The role of SSADH
appears to primarily metabolise a toxic by-product of glutamate
and GABA metabolism–SSA and, accordingly inhibiting its
activity would be anticipated to have deleterious effects. However,
the tetrameric nature of SSADH as well as analysis of related
molecules suggest that SSADH may be allosterically regulated.
Such a feature, if supported through experimental data, may
potentially be useful to improve SSADH function and SSA
degradation in cases of partial SSADH deficiency.
Materials and Methods
Gene Cloning, Expression and Purification
The cDNA encoding SSADH was isolated from E. coli MC1061
genomic DNA using PCR with the following primers 59ccagaatt-
caatgaaacttaacgacagtaac and 59cccagatctaagcttaaagaccgatgcacata-
tatttg and then cloned into pCRH -Blunt (Invitrogen). The DNA
sequence of the PCR product was shown to have a single amino
acid change to that of the gabD gene sequence in the database,
which is thought to represent a naturally occurring variant in E.
coli, the SSADH cDNA was excised from the recombinant pCRH -
Blunt vector using the restriction enzymes EcoRI and HindIII, then
ligated into pRSETc/His_TEV plasmid as previously described
Figure 5. SSADH substrate binding and the active site. A cartoon
representation of the E. coli SSADH (monomer A: green) substrate (SSA)
binding pocket superposed onto human SSADH C340A mutant with
SSA bound (PDB ID: 2w8q [26]: red) and human SSADH containing the
catalytic cysteine (PDB ID: 2w8o [26]: yellow). The key SSA binding
residues from 2w8q have their interactions with SSA shown as a red
dashed line. Superposition of catalytic residues are shown: the catalytic
cysteine and the general base as sticks (labeled according the E. coli
SSADH) and NADP
+ (orange) from E. coli SSADH. It can be seen that the
equivalent SSA binding residues from 2w8o and E. coli SSADH (R164,
R283 and S445) are in a very similar location and orientation to those of
2w8q. The catalytic cysteine of 2w8o is oriented toward the NADP
+
moiety while in E. coli C288 is oriented toward the substrate (SSA). Also
two conformations of the general base (E254) can be seen in E. coli




+ binding of E. coli SSADH. Stereo view of the active site showing the NADP
+ moiety (yellow), SSADH residues (green) involved in
binding NADP
+, water molecules can be seen as red spheres and all bonds are depicted with a black dashed line. The 2F0–Fc omit electron density of
the NADP
+ moiety contoured at 1s is also shown (light blue mesh). Interactions of monomer A and NADP
+ can be seen, specifically both AN1 and
AN6 of the adenine moiety (labelled adn) interacts with Q239(O
e1), Q243(O
e1) and N217(O
d1) via water molecules. Adjacent to the adenine moiety,
both AO2 and AO3 of the ribose (labelled rb2) hydrogen bonds with T153(O) and K179(N
Z, O) via a single water molecule. 3AOP of the 2’-phosphate
interacts with K179(N
Z). AO2 of the pyrophosphate interacts with S233(N, O
G) and the NO1 hydrogen bonds directly with W155(N
e1). Both NO2 and
NO3 of the adjacent ribose moiety (labelled rb1) hydrogen bonds with K338(N
Z), while NO2 also interacts with E385(O
e1). NN7 of the nicotinamide
(labelled nt) moiety interacts with N156(N
d2) and the catalytic C288(N) via the single water molecule. While NO7 interacts directly with G232(O) and
L255(O), as well as with L255(N) and E254(O
e1) via the same water molecule. Up to 13 SSADH residues make 24 van der Waals or hydrogen bonds
interactions with NADP
+ per monomer, 16 of which are mediated by water (Table S2). Notably, all of the residues involved directly NADP
+ binding in
E. coli SSADH [48] (Table S2) are also conserved in human SSADH.
doi:10.1371/journal.pone.0009280.g006
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BL21(DE3) pLysS cells and the transformant was stored at
280uC. For expression of SSADH recombinant protein, trans-
formed E. coli BL21(DE3) cells were propagated in 2YT growth
medium in the presence of 100 mg/mL ampicillin and 36 mg/ml
chloramphenicol at 37uCt oA 600=0.6 followed by induction at
16uC with 0.5 mM IPTG for 18 hours.
Harvested cells were treated with lysozyme (1 mg/ml) at 4uC
for 30 min and lysed in lysis buffer containing 300 mM NaCl,
10 mM imidazole, 5 mM b-mercaptoethanol, 0.01% triton X-
100, 50 mM Tris (pH 8.0) by sonication on ice. Clarified cell
lysate was loaded onto a Nickel Chelating Sepharose Fast Flow
column (GE healthcare), the His-tagged SSADH protein was
eluted in 150 mM NaCl, 250 mM imidazole, 5 mM b-mercap-
toethanol, 50 mM Tris (pH 8.0). Purified His-tagged SSADH
were further purified using a S200 16/60 size exclusion column
(GE Healthcare) pre equilibrated with 100 mM NaCl, 10 mM
b-mercaptoethanol, 5% glycerol, 30 mM Tris (pH 7.5) for all
experiments described in this paper.
Enzyme Kinetics and NMR Studies
Enzyme kinetics were carried out using purified SSADH (2 mg/
ml) in a Na phosphate buffer (100 mM pH 8.0), containing
1.1 mM NADP
+ and SSA 0–400 mM at 30uC. The rate at which
NADP
+ was converted to NADPH was monitored fluorometrically
(excitation: 355 nm and emission: 460 nm). SSADH oxidative
inhibition (H2O2) assays were carried out by incubating various
concentrations of H2O2 with SSADH (1 mg/ml) in a Na
phosphate buffer (100 mM pH 8.4), containing 0.75 mM EDTA
for 1 hour at room temperature, the reactions were terminated by
adding 5.0 mM methionine. To reverse the effect of the H2O2,
10 mM DTT was added to H2O2 treated SSADH and incubated
for a further 10 minutes. After the addition of 2.0 mM NADP
+
and 0.15 mM SSA, the activity of H2O2 treated SSADH was
measured spectrophotomically at 340 nm at 30uC.
1H NMR spectroscopic analysis was carried out with a Bruker
DPX 400 MHz spectrometer using purified SSADH in the
presence of 125 mM SSA for 240 min as above.
Figure 7. Different binding states of NAD(P)
+ in the ALDH
family. Four different conformations of NAD(P)
+ are shown as sticks,
hydride conformation (PDB ID: 1bpw[31]: yellow), hydrolysis conforma-
tion (E. coli SSADH: green), out conformation (PDB ID: 2ilu [29]:
magenta) and flexible, where the nicotinamide ribose moiety is unable
to be resolved using X-ray crystallography (PDB ID: 2w8r [26]: blue). The
general base (E254) and the catalytic cysteine (C288: both orange),
which are conserved in human and E. coli SSADH and the whole ALDH
family, have been labelled to define the active site.
doi:10.1371/journal.pone.0009280.g007
Table 1. Mutations causing nonsense mutations of SSADH









Q79Stop 11 residues of N-term.
Y128 Stop 60 residues of N-term.
K192 Stop 124 residues of N-term.
W204 Stop 136 residues of N-term.
R261 Stop 206 residues of N-term.
R412 Stop 357 residues of N-term.
R514 Stop 459 residues, missing one strand in the
oligomerisation domain only.
Deletions S35fs X49 Stop Missing all residues of the mature protein.
S55fs X79 Stop Missing all residues of the mature protein.
H154fs X10 Stop 86 residues of N-term.
S208fs X2 Stop 140 residues of N-term.
V392fs X10 Stop 337 residues, Missing half of the catalytic
and one strand of the oligomerisation
domains and helix 13 of the cofactor
binding domain.
A188fs X8 Stop 120 residues of N-term.
G488fs X5 Stop Missing last strand of the catalytic and
oligomerisation domains and helix 13 of





Missing entire Rossmann fold and catalytic
loop.
K 1 4 8 f sX 1 6S t o p 8 0r e s i d u e sN - t e r m .
Exon 5 deleted,
L243-K290 deleted
Missing last strand of the Rossmann fold
and the catalytic loop.
Exon 5 deleted,
L243-K290 deleted
Missing last strand of the Rossmann fold
and the catalytic loop.
F449fs X53 Stop 394 residues, Missing2 strands and2 helices
of the catalytic and one strand of the
oligomerisation domains and helix 13
of the cofactor binding domain.
Exon 7 deleted,
292-344 deleted




Missing 2 strands and 2 helices of the
catalytic and one strand of the
oligomerisation domains and helix
13 of the cofactor binding domain.
Insertions C93-R99
duplication
Duplication in loop between s2A and the
start of helix h1.
A12 fs X123 Stop Missing entire mature protein
A 1 5 3 f sX 1 2S t o p 8 5r e s i d u e sN - t e r m .
P442fs X18 Stop Missing 3 strands and 2 helices of the
catalytic and one strand of the
oligomerisation domains and helix 13
of the cofactor binding domain.
fs=frameshift; X=number of missense residues after the frameshift; Stop=stop
codon, termination of the protein.
Resulting SSADH protein size has been calculated excluding the 47 amino acid
N-terminal mitochondrial signal peptide, the mature protein size is 488
residues. All mutations previously published [9,36,37,38,40,41,42,60,61].
doi:10.1371/journal.pone.0009280.t001
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Pure SSADH was concentrated to 6 mg/mL and buffer
exchanged into 20 mM NaCl, 10 mM b-mercaptoethanol, 5%
glycerol, 1.0 mM NADP, 1.0 mM succinic semialdehyde, 30 mM
Tris (pH 7.5) using a 10 KDa molecular weight cut off
concentrator (Millipore).
Crystals of SSADH were grown using hanging drop vapour
diffusion by mixing 2.0 mL of protein (6 mg/mL) with 1.0 mLo f
reservoir solution containing 0.2 M ammonium tartrate, 26–31%
polyethylene glycol 3350, 10 mM b-mercaptoethanol and 0.1 M
Tris (pH 7.2–7.5). Crystals were dehydrated for 48 hours in 0.2 M
ammonium tartrate, 32% polyethylene glycol 3350, 10 mM b-
mercaptoethanol and 0.1 M Tris (pH 7.2–7.5) after three days.
Crystals were soaked in reservoir solution supplemented with 5%
2-methyl-2,4-pentanediol for 5 minutes then soaked for a further 5
minutes in reservoir solution supplemented with 10% 2-methyl-
2,4-pentanediol for cryoprotection before freezing in liquid
nitrogen for data collection. Data were collected at the Australian
Synchrotron High-throughput protein crystallography (PX1)
beam.
Structure Determination and Refinement
SSADH crystals diffracted to 2.3 A ˚ resolution and belong to the
space group P4212 with unit cell dimensions of a=151.88 A ˚,
b=151.88 A ˚, c=165.77 A ˚, a=b=c=90.0u. These data are
consistent with four molecules in the asymmetric unit. These data
were merged and scaled using MOSFLM [47] and SCALA [48].
Subsequent crystallographic and structural analysis was done using
the CCP4i interface to the CCP4i suite unless stated otherwise.
Figure 8. Human point mutations mapped onto the E. coli
SSADH structure. A cartoon representation of E. coli SSADH monomer
A (cyan, NADP
+ orange) showing the 17 point mutations (magenta
spheres) that map to the mature human protein. A small region of
monomer B catalytic domain(dark grey)andmonomer C oligomerisation
domain (light grey) have been included to illustrate the proximity of
point mutations with regard to dimer and tetramer interfaces. The
mutations occur in all three domains, 4 in the oligomerisation domain
(G176R, H180Y, P182L and G533R), 6 in the cofactor binding domain
(C93F, C223Y, T233M, A237S, N255S and G268E) and 7 in the catalytic
domain (N335K, N372S, P382L/Q, V406I, G409D and V487E).
doi:10.1371/journal.pone.0009280.g008
Table 2. Analysis of point mutations found in human SSADH enzymes as a result of missense mutations.
Mutated
Residue
% Activity of WT








A 87% Small polar to large basic polar N/A N/A N/A
C93F
B 3.0% Small non-polar to large non-polar M44 Loop between s2A & h1 Possible interaction with
Rossmann fold
G176R
B ,1.0% Small polar to large basic polar G127 Strand s1B Intermolecular tetramer contact
H180Y
AC 83% Both large intermediate polarity P131 Loop between s1B & s2B Intermolecular contact region
P182L
AC 48% Small non-polar to large non-polar H133 Loop between s1B & s2B Intermolecular dimer contact
C223Y
B 5.0% Small non-polar to large intermediate polarity C174 Loop between h4 & s4C Rossmann fold
T233M
B 4.0% Small non-polar to large non-polar T184 Loop between s4C & h5 Rossmann fold
A237S
A 65% Small non-polar to small polar A188 Helix h5 Rossmann fold
N255S
B 17% Both small polar N206 Strand s5C Rossmann fold
G268E
B ,1.0% Small polar to large acidic polar G216 Helix h6 Rossmann fold
N335K
B 1.0% Small polar to large basic polar N283 Loop between h8 & s4D Catalytic loop
N372S
C n.d. Both small polar D319 Loop between h9 & h10 Catalytic domain
P382L
B 2.0% Small non-polar to large non-polar P329(a) Loop between h9 & h10 Catalytic domain
P382Q
B n.d. Small non-polar to larger polar P329(b) Loop between h9 & h10 Catalytic domain
V406I
C n.d. Both non-polar V353 Strand s1D Catalytic domain
G409D
B ,1.0% Small polar to small acidic polar G356 Loop between s1D & s2D Catalytic domain
V487E
B n.d. Large non-polar to large acidic polar Y434 Strand s7D Intermolecular contact region
G533R
B ,1.0% Small polar to large basic polar G480 Strand s3B Intermolecular contact
Bold denotes conserved residue between human SSADH and E. coli SSADH.
n.d.=not determined.
ADenotes non-pathogenic point mutations found in patients with SSADH deficiency.
BDenotes pathogenic point mutations found in patients with SSADH deficiency.
CAllelic polymorphisms found in the general population
All mutations and reaction rates previously published [9,36,42,60].
doi:10.1371/journal.pone.0009280.t002
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nor a low-resolution cut-off applied to the data. Summaries of the
statistics are provided in Table 3. The completeness of the data is
relatively low (87%) due to overlaps caused by close spots, a result
of the beam being centred on the long cell edge of the unit cell.
The structure of SSADH was solved using molecular replace-
ment and the program PHASER [49]. A five-model ensemble was
constructed in PHASER using the structures that possess closest
sequence identity to SSADH (identified using the FFAS server
[50]: 5-carboxymethyl-2-hydroxymuconate semialdehyde (PDB
ID: 2d4e; unpublished), aldehyde dehydrogenase A (PDB ID:
2hg2)[29], aldehyde dehydrogenase (PDB ID: 1bxs)[34], formylte-
trahydrofolate dehydrogenase (PDB ID: 2o2p)[51] and putative
betaine aldehyde dehydrogenase (PDB ID: 1wnb)[30].
A ‘mixed’ model consisting of conserved side chains with all
other non-alanine/glycine residues truncated at Cc atom was then
created using the SCRWL server [52]. The five-model ensemble
was used as a search model in PHASER and a model based on
2o2p with an initial solution with a Z score of 44.8 that packed
well within the unit cell was identified. Together with the unbiased
features in the initial electron density, these data suggested a
correct molecular replacement solution.
Refinement and model building preceded using one molecule
(chain A) in the asymmetric unit, with the other chains built using
non-crystallographic symmetry operators. Maximum likelihood
refinement using REFMAC[53] was carried out using bulk solvent
correction (Babinet model). Tight NCS restraints were imposed on
all residues in the four molecules in the asymmetric unit, NCS
restraints were relaxed in flexible regions as suggested by
monitoring of the Rfree. Model building and structural validation
was performed using COOT [54]. Water molecules were added to
the model using ARP/warp [55] when the Rfree reached 28%. The
presence of each water molecule was manually validated. The
NADP
+ moiety was modelled into the density using PHENIX
ligandfit [56,57]. The stereochemical qualities of the final model
was checked by MolProbity [58] (96
th percentile; Table 3).
Accession Numbers and Datasets
Coordinates and structure factors have been deposited in the
Protein Data Bank with accession number 3jz4.
Diffraction image datasets and refinement logs are available
online on TARDIS (http://hdl.handle.net/102.100.100/42) [59].
Supporting Information
Figure S1 The conversion of SSA to SA using 1H NMR
spectroscopy. NMR spectra of (a) substrate alone in phosphate
buffer which contains succinic semialdehyde (X), 4,4-dihydrox-
ybutanoic acid (Y) and succinic acid (Z). (b) Succinic acid alone
with phosphate buffer, showing only the singlet peak of succinic
acid (Z). For SSADH enzyme assay, incubation of succinic
semialdehyde and SSADH in the presence of NADP+ at 0 min (c)
and 240 min (d) showing all substrates (X, Y, Z) has been
converted to succinic acid (Z), NADP+ is marked with W.
Found at: doi:10.1371/journal.pone.0009280.s001 (0.21 MB TIF)
Figure S2 Alignment of E. coli SSADH with human SSADH.
Conserved residues have been highlighted according to the
following, polar (green), non-polar (yellow), acidic (red) and basic
(blue). The secondary structure (E. coli SSADH above the sequence
and human below the sequence) has been marked with either an
arrow designating a I ˆ2-sheet or a cylinder representing an I ˆ6-helix.
The secondary structure elements are coloured according the
Figure 2a. Structurally important regions have also been marked
and labelled, catalytic loop (red line) and the GXXXXG motif (box)
from the Rossmann fold. The human SSADH mitochondrial
targeting sequence is labelled and shown as a blue line.
Found at: doi:10.1371/journal.pone.0009280.s002 (1.46 MB TIF)
Figure S3 SSADH activity in an oxidised and reduced
environment. The first column shows the untreated activity of
SSADH. In the second column the E. coli SSADH enzyme was
oxidised by incubating it with 200 I ˆJM H2O, which has 11–13%
of untreated SSADH activity. In the third column the addition of
10 mM DTT to previously oxidised enzyme, which rescued the
inhibition to 80% that of the normal activity.
Found at: doi:10.1371/journal.pone.0009280.s003 (0.16 MB TIF)
Figure S4 A–F. Human point mutations causing a dramatic loss
of acticvity (#2% residual SSADH) mapped onto the E. coli
SSADH structure. A cartoon representation of E. coli SSADH
monomer A (cyan, NADP+ orange) showing the 17 point
mutations (magenta spheres) that map to the mature human
protein. A small region of monomer B catalytic domain (dark grey)
and monomer C oligomerisation domain (light grey) have been
included to illustrate the proximity of point mutations with regard
to dimer and tetramer interfaces. Labelled, dashed red boxes
highlight the area of E. coli SSADH that have been enlarged for
analysis. A–F) Show the equivalent E. coli SSADH residues
(magenta sticks) to the human point mutants and their interactions
(black dashed lines) within their immediate surrounds with other
residues (orange sticks). A–B) Mutations in this region would be
anticipated to disrupt dimer and tetramerisation, while C) we




a, b, c (A ˚) 151.9, 151.9, 165.8
a, b, c,( A ˚) 90, 90, 90







Resolution (A ˚)2 . 3
Total nu. of obs. 1300495







Bond lengths (A ˚) 0.010
Bond angles (u)1 . 3
Molprobity score 8.45 (96
th percentile)
*Values in parenthesis are for the highest resolution shell.
doi:10.1371/journal.pone.0009280.t003
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PLoS ONE | www.plosone.org 10 February 2010 | Volume 5 | Issue 2 | e9280would anticipate decreased stability in this region due to loss of
stabilising interactions with the N255S mutation. D) A loss of
NAD/P+ binding efficiency would be expected with the addition
of a large negatively charged residue, G268E, into the positively
charged adenosine-ribose binding pocket of SSADH. E) We
anticipate an overall loss of structural integrity of this loop region
from either of the mutations G409D (loss of +/+ backbone
conformation) and P382L/Q (disruption of aromatic ring stacking
interactions with F419). F) The introduction of a large charged
residue (N335K) in a buried surface on the catalytic loop would be
anticipated to greatly disrupt the structural integrity and catalytic
ability of SSADH.
Found at: doi:10.1371/journal.pone.0009280.s004 (2.71 MB TIF)
Table S1 Intermolecular contacts with respect to monomer A.
Found at: doi:10.1371/journal.pone.0009280.s005 (0.18 MB
DOC)
Table S2 Residues involved in significant NADP+ binding using
Molprobity [58].
Found at: doi:10.1371/journal.pone.0009280.s006 (0.07 MB
DOC)
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